Search Results - "Laskar, M. Ghosh"

Treatment with the natural FXR agonist chenodeoxycholic acid reduces clearance of plasma LDL whilst decreasing circulating PCSK9, lipoprotein(a) and apolipoprotein C‐III by Ghosh Laskar, M., Eriksson, M., Rudling, M., Angelin, B.

“…Background The natural farnesoid X receptor (FXR) agonist chenodeoxycholic acid (CDCA) suppresses hepatic cholesterol and bile acid synthesis and reduces…”
Get full text

Treatment with the natural FXR agonist chenodeoxycholic acid reduces clearance of plasma LDL whilst decreasing circulating PCSK 9, lipoprotein(a) and apolipoprotein C‐ III by Ghosh Laskar, M., Eriksson, M., Rudling, M., Angelin, B.

“…Abstract Background The natural farnesoid X receptor ( FXR ) agonist chenodeoxycholic acid ( CDCA ) suppresses hepatic cholesterol and bile acid synthesis and…”
Get full text

Elective nodal dose of 60 Gy or 50 Gy in head and neck cancers: A matched pair analysis of outcomes and toxicity by Murthy, Vedang, MD, DNB, Gurram, Lavanya, MD, Kannan, Sadhana, MSc, Gandhi, Minakshi, MSc, Gupta, Tejpal, MD, DNB, Laskar, Sarbani Ghosh, MD, DNB, Budrukkar, Ashwini, MD, DNB, Agarwal, Jai Prakash, MD

“…Abstract Purpose The main objective of this study was to evaluate appropriate doses for elective nodal irradiation (ENI) in head and neck squamous cell…”
Get full text

Posttranscriptional regulation of the LDLR by ACTH treatment – Importance of PCSK9 in liver while idol takes the scene in the adrenals by Laskar, M. Ghosh, Angelin, B, Rudling, M

Get full text

Effect of COVID-19 Pandemic on Gynecological Cancer Radiation During Complete Nationwide Lockdown: Observations and Reflections From Tertiary Care Institute in India by Shinghal, Abhishek, Paul, Sonz, Chopra, Supriya, Gurram, Lavanya, Scaria, Libin, Kohle, Satish, Rane, Priyanka, A, Dheera, Puravath, John, Jain, Jivanshu, Swamidas, Jamema, Ghosh, Jaya, Gupta, Sudeep, Rath, Sushmita, Laskar, Sarbani Ghosh, Agarwal, Jai Prakash

“…To report real-world compliance to radiation in gynecologic cancers during the complete lockdown phase of COVID-19 pandemic. From March 23, 2020, until June…”
Get full text

Management of T2N0 Esophageal Cancer by Pramesh, C.S., MS, FRCS, Jiwnani, Sabita, MS, MRCS, Karimundackal, George, MCh, MRCS, Laskar, Sarbani Ghosh, MD

Get full text

Prognostic Factors and Outcome Analysis of Submandibular Gland Cancer: A Clinical Audit by Mallik, Suman, MD, DNB, Agarwal, Jaiprakash, MD, Gupta, Tejpal, MD, DNB, Kane, Shubhada, MD, Laskar, Sarbani Ghosh, MD, DNB, Budrukkar, Ashwini, MD, DNB, Murthy, Vedang, MD, Goel, Vineeta, MD, DNB, Jain, Sandeep, MD

“…Purpose To retrospectively review a long-term, single-institution experience of subjects with submandibular gland malignancies treated with definitive…”
Get full text

Postoperative Radiotherapy After Esophagectomy: Ripe for a Randomized Trial by Jiwnani, Sabita, MS, MRCS, Karimundackal, George, MCh, MRCS, Pramesh, C.S., MS, FRCS, Laskar, Sarbani Ghosh, MD

Get full text

Interobserver Variability in the Delineation of Gross Tumour Volume and Specified Organs-at-risk During Intensity Modulated Radiation Therapy for Head and Neck Cancers and the Impact of Fluoro-deoxy-glucose Positron Emission Tomography/Computed Tomography on Such Variability at the Primary Site by Gudi, Shivakumar, MD, Ghosh-Laskar, Sarbani, MD, DNB, Agarwal, Jai Prakash, MD, Chaudhari, Suresh, MSc, DipRP, Rangarajan, Venkatesh, MD, Nojin Paul, Siji, MSc, DipRP, Upreti, Rituraj, MSc, DipRP, Murthy, Vedang, MD, DNB, Budrukkar, Ashwini, MD, DNB, Gupta, Tejpal, MD, DNB

“…Abstract Purpose To assess interobserver variability (IOV) in the delineation of structures during intensity-modulated radiation therapy for head and neck…”
Get full text